ReviewAntioxidants (Basel, Switzerland)2021
Melatonin and Cancer: A Polyhedral Network Where the Source Matters.
Review in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 56 citations in OpenAlex.
- Nocturnal Melatonin Deficiency in Colorectal Cancer: Independent Predictive Value Beyond Sleep Quality.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Running out the clock: Circadian rhythm dysfunction in cognitive disease.International review of neurobiology · 2026Review
- Circadian rhythms as a modulator of gut microbiota-tumor microenvironment crosstalk.Cellular and molecular life sciences : CMLS · 2025Review
- Osteoprotective Effects of Melatonin on Bone Loss Associated with Dopaminergic Neuron Degeneration in a Rat Model of Parkinson Disease.Calcified tissue international · 2025Article
- Relationship between daytime napping duration and pan-cancer risk: a prospective cohort study based on the China Health and Retirement Longitudinal Study (CHARLS).Journal of health, population, and nutrition · 2025Article
- Exploring the Interplay Between Gut Microbiota and the Melatonergic Pathway in Hormone Receptor-Positive Breast Cancer.International journal of molecular sciences · 2025Article
- Comparative Analysis of Melatonin and Polydeoxyribonucleotide: Possible Benefits of Co-Treatment Effects and Potential Synergistic Applicability.International journal of molecular sciences · 2025Review
- Melatonin MT1 Receptor Expression in Luminal Invasive Ductal Breast Carcinoma in Postmenopausal Women.Biomolecules · 2025Article
- Circadian system and aging: where both times interact.Frontiers in aging · 2025Review
- Different color lights on refractive status and secretion of neurotransmitters in the guinea pig model of myopia.International journal of ophthalmology · 2025Article
- Melatonin: a natural guardian in cancer treatment.Frontiers in pharmacology · 2025Review
- Circadian rhythms and cancer: implications for timing in therapy.Discover oncology · 2024Review
- The interplay among sleep patterns, social habits, and environmental cues: insights from the Spanish population and implications for aligning daily rhythms.Frontiers in physiology · 2024Article
- Antitumoral melatonin-loaded nanostructured lipid carriers.Nanomedicine (London, England) · 2024Article
- Melatonin as a Mediator of the Gut Microbiota-Host Interaction: Implications for Health and Disease.Antioxidants (Basel, Switzerland) · 2023Review
- The tremendous clinical potential of the microbiota in the treatment of breast cancer: the next frontier.Journal of cancer research and clinical oncology · 2023Review
- Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma.Oxidative medicine and cellular longevity · 2023Article
- Sirtuins mediate mitochondrial quality control mechanisms: a novel therapeutic target for osteoporosis.Frontiers in endocrinology · 2023Review
- Interactions of melatonin with various signaling pathways: implications for cancer therapy.Cancer cell international · 2022Review
- Melatonin Reverses the Warburg-Type Metabolism and Reduces Mitochondrial Membrane Potential of Ovarian Cancer Cells Independent of MT1 Receptor Activation.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Melatonin is one of the most phylogenetically conserved signals in biology. Although its original function was probably related to its antioxidant capacity, this indoleamine has been "adopted" by multicellular organisms as the "darkness signal" when secreted in a circadian manner and is acutely suppressed by light at night by the pineal gland. However, melatonin is also produced by other tissues, which constitute its extrapineal sources. Apart from its undisputed chronobiotic function, melatonin exerts antioxidant, immunomodulatory, pro-apoptotic, antiproliferative, and anti-angiogenic effects, with all these properties making it a powerful antitumor agent. Indeed, this activity has been demonstrated to be mediated by interfering with various cancer hallmarks, and different epidemiological studies have also linked light at night (melatonin suppression) with a higher incidence of different types of cancer. In 2007, the World Health Organization classified night shift work as a probable carcinogen due to circadian disruption, where melatonin plays a central role. Our aim is to review, from a global perspective, the role of melatonin both from pineal and extrapineal origin, as well as their possible interplay, as an intrinsic factor in the incidence, development, and progression of cancer. Particular emphasis will be placed not only on those mechanisms related to melatonin's antioxidant nature but also on the recently described novel roles of melatonin in microbiota and epigenetic regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.